FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed is a recombinant cell line PSCA-CAR-YT, having surface expression of chimeric antigenic receptors and exhibiting cytotoxic activity with respect to PSCA-positive human cancer cells.
EFFECT: present invention can find further application in therapy of PSCA-associated cancer.
1 cl, 5 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT CYTO-CAR-YT-LACT CELL LINE EXHIBITING HIGH CYTOTOXIC ACTIVITY WITH RESPECT TO PSCA-POSITIVE HUMAN CANCER CELLS | 2019 |
|
RU2724431C1 |
| RECOMBINANT HUMAN BREAST CANCER CELL LINE BRCCH4E-134, EXPRESSING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN | 2019 |
|
RU2726541C1 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| RECOMBINANT CELL LINE TMDK562-15 SHOWING THE ABILITY TO ACTIVATE AND PROLIFERATE HUMAN NK CELLS | 2022 |
|
RU2803178C1 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
| POLYEPITOPE IMMUNOGENIC POLYPEPTIDES AND METHODS OF APPLICATION THEREOF | 2013 |
|
RU2598265C2 |
| CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | 2015 |
|
RU2764074C2 |
| HEMOPOIETIC CELL CD34+ AND USE THEREOF | 2005 |
|
RU2390558C2 |
